FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1549596568> ?p ?o ?g. }

• W1549596568 endingPage "844" @default.
• W1549596568 startingPage "836" @default.
• W1549596568 abstract "BACKGROUND The open‐label, single‐arm enzalutamide expanded access program (EAP) in the United States and Canada evaluated the safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer (mCRPC) who had previously received docetaxel. METHODS Patients (n = 507) received enzalutamide 160 mg/day until disease progression, intolerable adverse events (AEs), or commercial availability occurred. AEs and other safety variables were assessed on day 1, weeks 4 and 12, and every 12 weeks thereafter. Data following transition to commercial drug were not collected. RESULTS Median age was 71 years (range 43–97); 426 patients (83.9%) had a baseline ECOG score of ≤1. In addition to docetaxel, the majority of patients had received prior prostate cancer treatments such as abiraterone (76.1%) or cabazitaxel (28.6%). Median study treatment duration was 2.6 months (range 0.03–9.07). The most frequently reported reasons for discontinuation were commercial availability of enzalutamide (46.7%) and progressive disease (33.7%). A total of 88.2% of patients experienced AEs; 45.4% experienced AEs with a maximum grade of 1 or 2. Fatigue (39.1%), nausea (22.7%), and anorexia (14.8%) were the most commonly reported AEs. Seizure was reported in four patients (0.8%). The most commonly reported event leading to death was progression of metastatic prostate cancer (7.7%). CONCLUSION In this heavily pretreated EAP population with progressive mCRPC, enzalutamide was well tolerated and the safety profile was consistent with that of the AFFIRM trial. Prostate 75: 836–844, 2015. © 2015 The Authors. The Prostate , published by Wiley Periodicals, Inc." @default.
• W1549596568 created "2016-06-24" @default.
• W1549596568 creator A5002358672 @default.
• W1549596568 creator A5005231494 @default.
• W1549596568 creator A5014361897 @default.
• W1549596568 creator A5019963455 @default.
• W1549596568 creator A5042114199 @default.
• W1549596568 creator A5042123586 @default.
• W1549596568 creator A5043244227 @default.
• W1549596568 creator A5046123003 @default.
• W1549596568 creator A5053749991 @default.
• W1549596568 creator A5067610911 @default.
• W1549596568 creator A5078059658 @default.
• W1549596568 creator A5078094643 @default.
• W1549596568 creator A5083458032 @default.
• W1549596568 creator A5084129032 @default.
• W1549596568 creator A5085333470 @default.
• W1549596568 creator A5088466765 @default.
• W1549596568 creator A5088518998 @default.
• W1549596568 date "2015-02-14" @default.
• W1549596568 modified "2023-10-07" @default.
• W1549596568 title "Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America" @default.
• W1549596568 cites W1512914561 @default.
• W1549596568 cites W1965002585 @default.
• W1549596568 cites W1996389184 @default.
• W1549596568 cites W2014476883 @default.
• W1549596568 cites W2018899393 @default.
• W1549596568 cites W2020740347 @default.
• W1549596568 cites W2022635468 @default.
• W1549596568 cites W2066112327 @default.
• W1549596568 cites W2078699963 @default.
• W1549596568 cites W2080439368 @default.
• W1549596568 cites W2103959341 @default.
• W1549596568 cites W2110534364 @default.
• W1549596568 cites W2118564089 @default.
• W1549596568 cites W2119504728 @default.
• W1549596568 cites W2120292596 @default.
• W1549596568 cites W2121023961 @default.
• W1549596568 cites W2123526148 @default.
• W1549596568 cites W2140665438 @default.
• W1549596568 cites W2141454098 @default.
• W1549596568 cites W2148643283 @default.
• W1549596568 cites W2165542862 @default.
• W1549596568 doi "https://doi.org/10.1002/pros.22965" @default.
• W1549596568 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5024054" @default.
• W1549596568 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25683285" @default.
• W1549596568 hasPublicationYear "2015" @default.
• W1549596568 type Work @default.
• W1549596568 sameAs 1549596568 @default.
• W1549596568 citedByCount "16" @default.
• W1549596568 countsByYear W15495965682015 @default.
• W1549596568 countsByYear W15495965682016 @default.
• W1549596568 countsByYear W15495965682017 @default.
• W1549596568 countsByYear W15495965682018 @default.
• W1549596568 countsByYear W15495965682019 @default.
• W1549596568 countsByYear W15495965682020 @default.
• W1549596568 countsByYear W15495965682021 @default.
• W1549596568 countsByYear W15495965682022 @default.
• W1549596568 countsByYear W15495965682023 @default.
• W1549596568 crossrefType "journal-article" @default.
• W1549596568 hasAuthorship W1549596568A5002358672 @default.
• W1549596568 hasAuthorship W1549596568A5005231494 @default.
• W1549596568 hasAuthorship W1549596568A5014361897 @default.
• W1549596568 hasAuthorship W1549596568A5019963455 @default.
• W1549596568 hasAuthorship W1549596568A5042114199 @default.
• W1549596568 hasAuthorship W1549596568A5042123586 @default.
• W1549596568 hasAuthorship W1549596568A5043244227 @default.
• W1549596568 hasAuthorship W1549596568A5046123003 @default.
• W1549596568 hasAuthorship W1549596568A5053749991 @default.
• W1549596568 hasAuthorship W1549596568A5067610911 @default.
• W1549596568 hasAuthorship W1549596568A5078059658 @default.
• W1549596568 hasAuthorship W1549596568A5078094643 @default.
• W1549596568 hasAuthorship W1549596568A5083458032 @default.
• W1549596568 hasAuthorship W1549596568A5084129032 @default.
• W1549596568 hasAuthorship W1549596568A5085333470 @default.
• W1549596568 hasAuthorship W1549596568A5088466765 @default.
• W1549596568 hasAuthorship W1549596568A5088518998 @default.
• W1549596568 hasBestOaLocation W15495965681 @default.
• W1549596568 hasConcept C121608353 @default.
• W1549596568 hasConcept C126322002 @default.
• W1549596568 hasConcept C126894567 @default.
• W1549596568 hasConcept C143998085 @default.
• W1549596568 hasConcept C197934379 @default.
• W1549596568 hasConcept C2776551883 @default.
• W1549596568 hasConcept C2777899217 @default.
• W1549596568 hasConcept C2778715236 @default.
• W1549596568 hasConcept C2778971682 @default.
• W1549596568 hasConcept C2780192828 @default.
• W1549596568 hasConcept C2781190966 @default.
• W1549596568 hasConcept C2908647359 @default.
• W1549596568 hasConcept C61367390 @default.
• W1549596568 hasConcept C71924100 @default.
• W1549596568 hasConcept C99454951 @default.
• W1549596568 hasConceptScore W1549596568C121608353 @default.
• W1549596568 hasConceptScore W1549596568C126322002 @default.
• W1549596568 hasConceptScore W1549596568C126894567 @default.
• W1549596568 hasConceptScore W1549596568C143998085 @default.
• W1549596568 hasConceptScore W1549596568C197934379 @default.

• next